BioSpace News Archive

Initiation of Phase 2 study of Cabiralizumab plus Opdivo in advanced pancreatic cancer.

The companies established this collaboration to explore the delivery of genome editing medicines to treat up to five inherited retinal diseases.

Reported revenue and procedure results are consistent with the Company’s press release on January 10, 2018.

The addition of a senior executive of Tim’s caliber is another proof point as we advance our strategy to meet U.S. demand

Mr. Rasschaert will be responsible for overseeing sales of the Company’s FDA-approved STREAMWAY System for automated, direct-to-drain medical fluid disposal to hospitals and medical centers across Europe.

A second subscription phase is currently taking place, and the Company has every hope it will obtain a swift subscription of the remaining €2 million of shares that can still be subscribed to on the basis of the approval granted by the Shareholders Meeting on 7 December.

The US Patent and Trademark Office previously upheld the validity of the patents rejecting multiple challenges filed by Ariosa.

Verastem today announced that a poster highlighting the synergistic effects of duvelisib in combination with immune checkpoint or co-stimulatory antibodies in preclinical models of B cell lymphoma was presented at ASCO-SITC Clinical Immuno-Oncology Symposium being held January 25-27, 2018 in San Francisco.

Ferring Pharmaceuticals today announced the recipients of the 2017-2018 Innovation Grants Program, an annual initiative of the Ferring Research Institute (FRI) based in San Diego.

Concept will become a separate operating company within its Materials Analysis segment where it has strong synergies with the activities of Malvern Panalytical.